**Multiple Sclerosis**

## Syndicated Thought Leader Insight

# *Thought Leader Insight & Analysis* Report
# Multiple Sclerosis Q3 2011

| | |
|---|---|
| **Therapeutic Class:** | CNS Disorders |
| **Focus Area:** | Multiple Sclerosis |
| **Specialty/Location:** | Neurologists/N. America |
| **Number of Interviews:** | 7 |
| **Number of Pages:** | 158 |
| **Publication Date:** | September 2011 |
| **Principal Authors:** | Tricia L. Hanlon<br>Kim Grant<br>Jeffrey D. Berk, Ph.D., MBA |
| **Product Code:** | MAIMQ311-14 |
| **Pricing:** | $7,500 |
| **Order Info:** | www.medpredict.com or call (513) 271-1924 |

**Abstract:**
Multiple Sclerosis Thought Leader Panel #14 highlights a series of interviews conducted with our experts in September, 2011. For this Panel we asked our Thought Leaders to engage in a thought exercise with us. The purpose was to designate their "fantasy formulary", comprised of the top seven therapeutics, currently in the development pipeline, that they want to see available for use in the prevention/treatment of multiple sclerosis. We allowed Panelists to choose the class of drug, a specific drug (if they had a preference), the unmet needs to be addressed and the benefits that they expected their choices to deliver. The panel's responses are just as enlightening regarding what they would NOT put on their fantasy formularies. This is the second iteration of this exercise, and for comparison we include *normalized* results (see scoring explanation) from Multiple Sclerosis Thought leader Panel #11, published in June 2010.

**Full transcripts of 7 qualitative interviews with neurologists are included with this report.**

# Table of Contents

**EXECUTIVE SUMMARY 4**
**FANTASY FORMULARY - GROUND RULES AND SCORING 4**

**Multiple Sclerosis Fantasy Formulary Results (2011) ..... 5**

**Multiple Sclerosis Fantasy Formulary Results (2010) ..... 7**

**Data Tables ..... 9**
Table 1a: Preferred Product Classes (2011) ..... 9
Table 1b: Preferred Product Classes (2010) ..... 10
Table 2a: Individual Thought Leader Rankings (2011) ..... 11
Table 2b: Individual Thought Leader Rankings (2010) ..... 13
Table 3a: Most Frequent Favorably Mentioned Drugs (2011) ..... 15
Table 3b: Most Frequent Favorably Mentioned Drugs (2010) ..... 16

**DISCUSSION - PREFERRED PRODUCT CLASSES 17**

**Oral Immunomodulators ..... 17**
Panaclar; BG-00012; BG-12; fumarate (Biogen-Idec) ..... 17
laquinimod (Teva) ..... 24
teriflunomide (Sanofi-Aventis) ..... 30

**B-Cell Inhibitors ..... 38**
CD20 ..... 38
Ocrelizumab / rituximab (Roche / Genentech / Biogen-Idec) ..... 38
Ofatumumab (Genmab / GSK) ..... 47
CD19 ..... 49
MEDI-551 (Medimmune) ..... 49

**Neuroregeneration ..... 50**
LINGO-1 (Biogen-Idec) ..... 50
VX-15 (anti-SEMA4D; Vaccinex) ..... 55
anti-NOGO (GlaxoSmithKline) ..... 55

**S1P Receptor Agonists ..... 56**
Gilenya; fingolimod (Novartis) ..... 57
XL-9953 (Boehringer-Ingelheim / Exelixis) ..... 63
BAF-312 (KRP-203, Kyorin / Novartis) ..... 63
Ponesimod / ACT-128800 (Actelion) ..... 64
ONO-4641 (Ono) ..... 68

**Anti-CD-25 (Anti-IL-2) ..... 69**
Zenapax (daclizumab; PDL Biopharma/Biogen/Roche) ..... 69

**VLA-4 ..... 72**
Tysabri; natalizumab (Biogen / Elan) ..... 72
sub-q VLA4 (Elan) ..... 75
firategrast (GlaxoSmithKline) ..... 76

**Long-Term Immunosuppressants ..... 76**
CD52 ..... 76
Lemdatra / Campath; anti-CD-52; alemtuzumab (Genzyme / Sanofi-Aventis / Bayer-Schering) 76



MedPredict® Market Research
Telephone: 513.271.1924 – Email: info@medpredict.com – Website: www.medpredict.com
Pharmaceutical Competitive Intelligence – Market Research – Conference Coverage

**DISCUSSION - OTHER PRODUCT MENTIONS 79**

**Neuropathic Pain ..... 79**
P2X7 ..... 79
AFC-5128 (Affectis) ..... 79
Ampakine (Not Specified) ..... 79

**GA Next Generation ..... 80**

**CTLA4 ..... 81**
Orencia / abatacept (BMS) ..... 81

**Microglial Activation Inhibition ..... 82**

**Stem Cells ..... 83**

**Bone Marrow Transplant ..... 84**

**Complement Activation ..... 84**

**Interferon ..... 85**
NU400 (PEGylated Interferon Beta-1b; Nuron) ..... 85

**Vaccines / Immune Tolerance ..... 86**
Tovaxin (Opexa) ..... 86

**DISCUSSION - WHAT DIDN'T MAKE THE LIST 87**
Mylinax (cladribine; Merck-Serono) ..... 87
atacicept (Merck-Serono) ..... 87
Ampyra / Fampyra; dalfampridine (Acorda / Elan / Biogen) ..... 89
CNDO-201 (Coronado) ..... 90

**THOUGHT LEADER DISCUSSIONS 92**
**Interview CNS02600 ..... 92**
**Interview CNS02602 ..... 101**
**Interview CNS02603 ..... 112**
**Interview CNS02604 ..... 122**
**Interview CNS02605 ..... 131**
**Interview CNS02606 ..... 141**
**Interview CNS02607 ..... 151**